Status: Available
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: StemCyte, Inc.Updated: Mar 23, 2026Locations: 2
Eligibility criteria
Male or female aged ≥ 18 [+5]
Neurological disorders prior to COVID-19 diagnosis [+7]